Ignite Creation Date:
2024-10-26 @ 3:40 PM
Last Modification Date:
2024-10-26 @ 3:40 PM
Study NCT ID:
NCT06597721
Status:
NOT_YET_RECRUITING
Last Update Posted:
None
First Post:
2024-09-12
Brief Title:
AMT-754 in Patients With Selected Advanced Solid Tumours
Sponsor:
None
Organization:
None
Study Overview
Official Title:
First-in-Human Phase 1 Study of AMT-754 a Targeting Tissue Factor Antibody-Drug Conjugate in Patients With Advanced Solid Tumors
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This first-in-human study will evaluate the Maximum Tolerated Dose MTD the Recommended Phase 2 Dose RP2D safety tolerability anti-tumor activity pharmacokinetics pharmacodynamics and immunogenicity of AMT-754 in Patients with Advanced Solid Tumors
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None